User profiles for Annabelle Biscans
 | Annabelle BiscansAstraZeneca R&D, Sweden Verified email at astrazeneca.com Cited by 895 |
Divalent siRNAs are bioavailable in the lung and efficiently block SARS-CoV-2 infection
The continuous evolution of SARS-CoV-2 variants complicates efforts to combat the ongoing
pandemic, underscoring the need for a dynamic platform for the rapid development of pan-…
pandemic, underscoring the need for a dynamic platform for the rapid development of pan-…
Diverse lipid conjugates for functional extra-hepatic siRNA delivery in vivo
Small interfering RNA (siRNA)-based therapies are proving to be efficient for treating liver-associated
disorders. However, extra-hepatic delivery remains challenging, limiting …
disorders. However, extra-hepatic delivery remains challenging, limiting …
[HTML][HTML] Rational design of a JAK1-selective siRNA inhibitor for the modulation of autoimmunity in the skin
Inhibition of Janus kinase (JAK) family enzymes is a popular strategy for treating inflammatory
and autoimmune skin diseases. In the clinic, small molecule JAK inhibitors show distinct …
and autoimmune skin diseases. In the clinic, small molecule JAK inhibitors show distinct …
Hydrophobicity drives the systemic distribution of lipid-conjugated siRNAs via lipid transport pathways
Efficient delivery of therapeutic RNA beyond the liver is the fundamental obstacle preventing
its clinical utility. Lipid conjugation increases plasma half-life and enhances tissue …
its clinical utility. Lipid conjugation increases plasma half-life and enhances tissue …
[HTML][HTML] Optimized cholesterol-siRNA chemistry improves productive loading onto extracellular vesicles
Extracellular vesicles are promising delivery vesicles for therapeutic RNAs. Small interfering
RNA (siRNA) conjugation to cholesterol enables efficient and reproducible loading of …
RNA (siRNA) conjugation to cholesterol enables efficient and reproducible loading of …
Innovative developments and emerging technologies in RNA therapeutics
RNA-based therapeutics are emerging as a powerful platform for the treatment of multiple
diseases. Currently, the two main categories of nucleic acid therapeutics, antisense …
diseases. Currently, the two main categories of nucleic acid therapeutics, antisense …
[HTML][HTML] Chemical optimization of siRNA for safe and efficient silencing of placental sFLT1
…, D Echeverria, J Sousa, N McHugh, A Biscans… - … Therapy-Nucleic Acids, 2022 - cell.com
Preeclampsia (PE) is a rising, potentially lethal complication of pregnancy. PE is driven
primarily by the overexpression of placental soluble fms-like tyrosine kinase 1 (sFLT1), a …
primarily by the overexpression of placental soluble fms-like tyrosine kinase 1 (sFLT1), a …
[HTML][HTML] Docosanoic acid conjugation to siRNA enables functional and safe delivery to skeletal and cardiac muscles
A Biscans, J Caiazzi, N McHugh, V Hariharan… - Molecular Therapy, 2021 - cell.com
Oligonucleotide therapeutics hold promise for the treatment of muscle- and heart-related
diseases. However, oligonucleotide delivery across the continuous endothelium of muscle …
diseases. However, oligonucleotide delivery across the continuous endothelium of muscle …
The valency of fatty acid conjugates impacts siRNA pharmacokinetics, distribution, and efficacy in vivo
Lipid-conjugated small-interfering RNAs (siRNAs) exhibit accumulation and gene silencing
in extrahepatic tissues, providing an opportunity to expand therapeutic siRNA utility beyond …
in extrahepatic tissues, providing an opportunity to expand therapeutic siRNA utility beyond …
The chemical structure and phosphorothioate content of hydrophobically modified siRNAs impact extrahepatic distribution and efficacy
Small interfering RNAs (siRNAs) have revolutionized the treatment of liver diseases.
However, robust siRNA delivery to other tissues represents a major technological need. …
However, robust siRNA delivery to other tissues represents a major technological need. …